174 related articles for article (PubMed ID: 12642031)
1. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
[TBL] [Abstract][Full Text] [Related]
3. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients.
Re MC; Vignoli M; Furlini G; Gibellini D; Colangeli V; Vitone F; La Placa M
J Clin Virol; 2001 Apr; 21(1):81-9. PubMed ID: 11255101
[TBL] [Abstract][Full Text] [Related]
7. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
Rodman TC; To SE; Hashish H; Manchester K
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
[TBL] [Abstract][Full Text] [Related]
8. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.
Nicoli F; Chachage M; Clowes P; Bauer A; Kowour D; Ensoli B; Cafaro A; Maboko L; Hoelscher M; Gavioli R; Saathoff E; Geldmacher C
BMC Infect Dis; 2016 Jul; 16():344. PubMed ID: 27450538
[TBL] [Abstract][Full Text] [Related]
9. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
[TBL] [Abstract][Full Text] [Related]
11. Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans.
Senkaali D; Kebba A; Shafer LA; Campbell GR; Loret EP; Van Der Paal L; Grosskurth H; Yirrell D; Kaleebu P
AIDS Res Hum Retroviruses; 2008 Apr; 24(4):587-94. PubMed ID: 18366309
[TBL] [Abstract][Full Text] [Related]
12. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
[TBL] [Abstract][Full Text] [Related]
13. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.
Rezza G; Fiorelli V; Dorrucci M; Ciccozzi M; Tripiciano A; Scoglio A; Collacchi B; Ruiz-Alvarez M; Giannetto C; Caputo A; Tomasoni L; Castelli F; Sciandra M; Sinicco A; Ensoli F; Buttò S; Ensoli B
J Infect Dis; 2005 Apr; 191(8):1321-4. PubMed ID: 15776379
[TBL] [Abstract][Full Text] [Related]
14. HIV regulatory and accessory proteins: new targets for vaccine development.
Robert-Guroff M
DNA Cell Biol; 2002 Sep; 21(9):597-8. PubMed ID: 12396601
[No Abstract] [Full Text] [Related]
15. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
16. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma.
Demirhan I; Chandra A; Hasselmayer O; Biberfeld P; Chandra P
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):364-8. PubMed ID: 10634198
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
[TBL] [Abstract][Full Text] [Related]
18. Co-immunization with an HIV-1 Tat transduction peptide-rotavirus enterotoxin fusion protein stimulates a Th1 mucosal immune response in mice.
Kim TG; Befus N; Langridge WH
Vaccine; 2004 Jan; 22(3-4):431-8. PubMed ID: 14670325
[TBL] [Abstract][Full Text] [Related]
19. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.
Reiss P; de Wolf F; Kuiken CL; de Ronde A; Dekker J; Boucher CA; Debouck C; Lange JM; Goudsmit J
J Acquir Immune Defic Syndr (1988); 1991; 4(2):165-72. PubMed ID: 1898969
[TBL] [Abstract][Full Text] [Related]
20. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
